drugset / Trial / NCT05114603
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation
Non-randomizedSequentialOpen-labelTreatment
Summary
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for advanced melanoma with BRAF V600 mutation
Timeline
- Start
- 2022-03-21
- Primary completion
- 2023-08-30
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX208 | Unknown | 600 mg | Oral |
| Subject | HLX208 | Unknown | 900 mg | Oral |